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ABSTRACT
Introduction: Lymphoma is the sixth most common
cancer diagnosed in Australia and internationally.
Owing to the aggressive nature of the disease and
intensity of treatment, survivors face long-term effects
that impact on quality of life. Current models of follow-
up post-treatment fail to address these complex issues.
Given that 74% of patients with lymphoma cancer now
survive 5 years beyond diagnosis and treatment, it is
important to address this gap in care.
Aim: To determine self-reported informational and
practical needs, anxiety, depression, stress, coping and
empowerment at baseline, 3 and 6 months.
Methods and analysis: A pilot randomised
controlled trial will test the effect of a nurse-led
lymphoma survivorship clinic compared with usual
post-treatment care at a large tertiary cancer centre in
Western Australia. The intervention will comprise three
face-to-face appointments with delivery of tailored
resources, a survivorship care plan and treatment
summary (SCP TS). The SCP TS will be given to the
participant and general practitioner (GP). Intervention
participants will be interviewed at completion to
explore the perceived value of the intervention
components and preferred dose. An evaluation
developed for GPs will assess receipt and use of SCP
TS. The primary intent of analysis will be to address
the feasibility of a larger trial and requisite effect and
sample size.
Ethics and dissemination: Ethics approval has been
granted by the University of Notre Dame Australia and
Sir Charles Gairdner Hospital in Western Australia.
Peer-reviewed publications and conference
presentations will report the results of this phase II trial.
Trial registration number: ANZCTRN126150005
30527; Pre-results.
INTRODUCTION
Lymphoma is a general term for over 20
blood cancers that originate from T and B
cells in the lymphatic system1 where
lymphocytes undergo a malignant change
and multiple uncontrollably. Lymphomas,
when combined, represent the sixth most
commonly diagnosed cancer worldwide,2
with Hodgkin’s lymphoma (HL) and
non-Hodgkin’s lymphoma (NHL) the two
main forms. HL represents 11.5% of all
lymphomas and is the third most common
cancer in the adolescent and young adult
population.1 With the exception of HL, inci-
dence increases with age; thus, NHL is pre-
dominantly a cancer of the older population
(over 65 years).1 3
The incidence of lymphoma in Australia is
increasing, with a projected diagnosis of
5680 cases in 2015. This will equate to 4.5%
of all cancer cases.4 In Australia, the overall
survival rate has improved, and ∼74% of
people diagnosed with lymphoma are
reported as being alive at 5 years compared
with 49% in the 1980s.4 Despite these
encouraging results,5 this group of cancers
remain understudied and subsequently
under-represented in survivorship care.6
Lymphoma treatment regimens commonly
involve aggressive high-dose chemotherapy
and/or targeted therapy agents, radiotherapy
Strengths and limitations of this study
▪ This is the first randomised controlled trial of a
nurse-led model of survivorship care for patients
completing treatment for lymphoma cancer in
Western Australia.
▪ This trial will test a developed lymphoma-specific
survivorship care plan and treatment summary.
▪ As a pilot study, it is designed to provide prelim-
inary data on the efficacy and feasibility of a
nurse-led survivorship intervention for the pur-
poses of planning a phase III study.
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and haematopoietic stem cell transplants.7 Such treat-
ments result in distressing long-term and late physical,
practical and psychosocial effects, which can produce
ongoing unmet needs. These needs relate to physical
and psychosocial impacts such as fear of recurrence,
fatigue, poor nutrition, exercise, fertility, relationship,
financial, employment and insurance issues.8
Furthermore, these patients commonly experience
related health problems earlier than the general popula-
tion9 and are at risk of specific late effects.
Cardiovascular disease is particularly pertinent in this
cohort due to chemotherapy combinations and cumula-
tive dosing10 11 as well as mediastinal radiotherapy.12 13
Patient health and lifestyle behaviours, for example,
smoking, likewise have an effect on disease develop-
ment.11 Patients with lymphoma have an increased rela-
tive risk of second cancers, higher when diagnosed at a
younger age14 15 and further elevated when treatment
includes radiotherapy.11 12 The potential for the devel-
opment of bone marrow disease is greater in the first
decade; however, unlike second cancer risk, this
decreases and then plateaus in the second decade.11
Patients who require a haematopoietic stem cell trans-
plant have additional transplant-related late-effect
risks.16 17 Although patients may be unable to modify
some late-effect risks, awareness of relevant potential late
effects may ensure timely follow-up for symptomology.11
The traditional model of haematological cancer care
follow-up has largely been haematologist led within the
acute hospital setting.8 Information at treatment comple-
tion is often inadequate,18 19 with a lack of clear guide-
lines for the ongoing management of survivors.20 This
has led to an emerging focus on redesigning survivor-
ship follow-up care and delivery.
Lobb et al21 demonstrated patient-reported needs
among Western Australian haematological cancer survi-
vors (n=66) not addressed during routine follow-up post-
treatment completion and thereby classified as unmet
needs. Almost two-thirds of respondents (59%) would
have found it helpful to talk with a health professional at
treatment completion. A recent qualitative study con-
ducted by the authors with lymphoma and leukaemia
cancer survivors (n=19) in Western Australia22 found
unmet needs relating to information, practical support,
coping strategies and transitioning from active treatment
into the survivorship phase. Findings suggested that tai-
lored, end-of-treatment interventions should form a key
component of survivorship care. Participants suggested a
cancer coordinator nurse as an important element to ini-
tiate and transition patients into the survivorship phase.
Nurse-led models of care have demonstrated poten-
tially satisfactory outcomes23–25 and are proposed as an
acceptable pathway to transition into the survivorship
phase.26 A dedicated nurse-led survivorship clinic to
administer patient-centred survivor-specific needs assess-
ments is an important aspect of survivorship care to
address patient concerns and empower survivors to
manage their own health and ongoing symptoms.27–30
Empowering patients enables them to become more
responsible for the management of their own health
and well-being, and can contribute to the influence and
control patients have over their own health which has
the advantage of improving quality of life.31 32 Bandura’s
theory of self-efficacy,33 the principal concept in self-
management education, teaches patients to identify
their problems and provides skills in decision-making
and developing an appropriate action plan.31 It is antici-
pated that increasing empowerment and providing
healthy lifestyle resources will result in a reduction in
the patient-perceived need for support from the health-
care system.31
Survivorship care plans (SCPs) and treatment summar-
ies (TS) have been recommended as facilitators to
deliver holistic survivorship follow-up care by the
Institute of Medicine,34 the American Society of Clinical
Oncology,35 the UK National Cancer Survivorship
Initiative36 and the proposed Clinical Oncology Society
of Australia survivorship guidelines.37 A personalised
SCP would guide follow-up care by including recommen-
dations, information and resources for surveillance,
screening of potential long-term and late effects and
health-promoting behaviours.38 The TS would compre-
hensively summarise information on diagnosis and treat-
ments.39 40 Cancer nurses have established expertise in
the areas of health promotion, information, support and
resource provision,41 and therefore can develop and dis-
seminate SCPs and TS to facilitate communication
between the survivor, specialist and primary care.
AIM
The aim of the Care After Lymphoma (CALy) study is
to develop and empirically test an evidence-based
nurse-led lymphoma survivorship clinic to transition par-
ticipants into the survivorship phase, using a pilot rando-
mised controlled trial (RCT) design. This phase II trial
of an intervention is aimed at reducing the immediate
and long-term physical and psychosocial consequences
of haematological cancer treatment and to enable the
participant to return to normal functioning sooner. The
nurse-led lymphoma survivorship clinic has three core
components: (1) needs assessments to determine indi-
vidual informational or practical issues or concerns; (2)
provision of a tailored survivorship care plan and treat-
ment summary to enhance communication between the
participant and all other health professionals with whom
the patient has contact post-treatment; and (3) provision
of individualised evidence-based education, information
and resources to address patient-reported needs, likely
post-treatment physical and emotional concerns and
maximising participant involvement in healthy lifestyle
behaviours. The aims are aligned with the Australian
national research priority for preventative healthcare to
reduce comorbid diseases in cancer survivors.
The Medical Research Council framework for the
development and evaluation of complex interventions
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has guided the development of this trial.42 43 The evalu-
ation of a model for nurse-led evidence-based survivor-
ship care will provide level II baseline data to endorse
the suitability of outcome measures, establish acceptabil-
ity of the intervention and randomisation, provide
recruitment and attrition rates, support hypothesis devel-
opment and calculate sample sizes for future phase III
multisite RCTs. In addition, it will add psychometric
information on the Short-Form Survivor Unmet Needs
Survey (SF-SUNS) and will provide data on a test–retest
analysis.
RESEARCH QUESTIONS
The following research questions guide this pilot RCT:
1. Do participants assigned to the nurse-led lymphoma
survivorship clinic demonstrate a reduction in per-
ceived unmet informational and practical needs com-
pared with those randomly assigned to usual care?
2. Do participants assigned to the nurse-led lymphoma
survivorship clinic demonstrate a reduction in self-
reported anxiety, depression and stress and an
increase in patient self-management behaviours com-
pared with participants randomly assigned to usual
care?
3. What is the perceived efficacy and value of the
nurse-led lymphoma survivorship clinic from the per-
spective of a subset of survivors in the intervention
group?
4. To what extent does the provision of an SCP TS to
general practitioners (GPs) improve the communica-
tion between the treating hospital, GP and the
participant?
5. Does the SF-SUNS demonstrate stability and reliabil-
ity over time?
METHODS
Design
The evidence to support the development of the phase
II CALy trial comprised a qualitative study using a focus
group methodology with lymphoma, leukaemia and
multiple myeloma survivors.22 The evidence also encom-
passed three systematic reviews regarding models of
haematological survivorship care; SCPs and TS in
patients with haematological cancer; and tools used to
assess the informational and practical needs of acute leu-
kaemia and lymphoma survivors.8 38 44 Information
gained from this preliminary work guided the develop-
ment of intervention components and the operationali-
sation of the feasibility and acceptability of a nurse-led
RCT.
The RCT framework has been developed using the
Consolidated Standards of Reporting Trials
(CONSORT) statement and checklist.45 46 Outcomes
will be measured using validated needs assessment
instruments. Reporting will include inclusion and exclu-
sion criteria; missing data; dropout; and early closure of
the trial if required (figure 1). The survivorship cancer
nurse coordinator (CNC) is a specialist cancer nurse
with an extensive haematology nursing background and
formal counselling qualifications, including motivational
interviewing techniques.
Population and setting
A convenience sample of patients with lymphoma
cancer from a specialised haematology department in a
comprehensive cancer centre of a large acute tertiary
hospital in Perth, Western Australia, will be used.
Follow-up by a haematologist occurs every 3 months for
the first 12 months. The nurse-led survivorship clinic
intervention will be an additional care activity to the
medical haematology follow-up and will involve three
appointments over 6 months. It will start at 3 months
post-treatment completion and cease at 9 months
post-treatment.
Inclusion criteria
1. Pathologically confirmed new diagnosis of HL or
NHL.
2. Completed first-line curative intent chemotherapy or
second-line curative intent autologous stem cell trans-
plant within the previous 3 months.
3. No evidence of lymphoma disease on mid-treatment
interim positron emission tomography (PET) scan or
post-treatment PET scan where these are performed.
4. Able to understand and read English.
5. Over 18 years.
Exclusion criteria
1. Diagnosis of other haematological malignancy.
2. Did not undergo chemotherapy.
3. Further treatment and follow-up at another hospital.
4. Intellectually impaired or experiencing an acute
mental health condition that precludes the ability to
provide informed consent.
5. Comorbid condition requiring monthly visits with GP.
To measure selection bias, minimal data will be com-
pleted on eligible participants who decline to partici-
pate. Reasons for refusal will be recorded to gain
valuable information for future research.
Recruitment
Identification of eligible participants will be undertaken
by haematology clinicians who will provide details to the
survivorship CNC. Ongoing education of clinicians (hae-
matologists and nurses) regarding all aspects of the
study, its progress and recruitment will facilitate cooper-
ation and support. Eligible participants will be met after
treatment completion by the CNC who will discuss the
study and provide a Participant Information and
Consent Form (PICF). Consenting participants rando-
mised to the intervention group (n=30) will be offered
the opportunity to consent to a qualitative interview at
completion of all time points. Approximately one-third
of participants (n=10) will be required for this phase.
Participants’ names and contact details will be entered
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onto a master coding sheet and assigned a numerical
identifier code after randomisation.
SCP and TS
An extensive review of the literature38 and available
SCPs and TS was undertaken. Many institutions in
Australia are using US-based templates that are large
(up to 20 pages), not tailored to the individual and
provide resources that are not contextualised to the
Australian healthcare setting. Therefore, we developed a
lymphoma SCP TS in collaboration with a haematology
consultant, GP and other multidisciplinary team
members (eg, consumers, psychologists, cancer nurses
and academic cancer researchers). This has been
created as a word document template to be filled in by
the nurse. The perspectives of lymphoma survivors
(n=6) and clinicians (including GPs; n=6) were sought
to determine the relevance of the proposed SCP TS
items. Each item was assessed for content and apparent
internal consistency (whether items should be included
and the general fit with other items) using either yes or
no responses to the items. Content validity used a rating
scale (1=not relevant to 4=highly relevant). The content
validity index (CVI)47 was generated for each item by
adding the number of ‘yes’ scores (content, clarity and
apparent internal consistency) and scores of 3 or 4
(content validity). The mean CVI consumer results were
as follows: clarity 0.98; apparent internal consistency
100; content validity 0.95. Consumers demonstrated
complete agreement of 1.0 for internal consistency
items. The mean CVI clinician results were as follows:
clarity 0.99; apparent internal consistency 0.95; content
validity 0.84. Feedback in the comments section of the
evaluation interestingly indicated GPs did not value or
Figure 1 Trial flow chart.
DASS-21, Depression Anxiety
Stress Scale; GP, general
practitioner; Mini-MACM,
Mini-Mental Adjustment to Cancer
Scale; PES, Patient
Empowerment Scale; PET,
positron emission tomography;
SCP TS, survivorship care plan
and treatment summary;
SF-SUNS, Short-Form Survivor
Unmet Needs Survey.
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require a large TS document. Consensus of the research
team was reached for the TS (half a page in length) and
SCP (one and a half pages in length).
The TS is completed using existing medical record
information such as diagnosis, treatment, complications
and use of allied health providers. The first section of
the SCP includes a table for the inclusion of individua-
lised potential late effects. This table comprises the late
effect; information for the GP about tests or follow-up
required and when; and the symptomology the partici-
pant needs to be aware of, with encouragement to
follow these up with the GP. Prior to recruitment, a com-
prehensive list of potential late effects and follow-up
required was developed for each lymphoma type using
available published literature and guidelines (KT). This
list was circulated, discussed and amended by the hae-
matologists who were aware these would be used to
guide their population of the table. Tailored individua-
lised potential late effects will be documented based on
treatments administered, participants’ demographics
and health characteristics. Once the TS and this aspect
of the SCP are completed, it will be emailed to the
haematologist for final approval. Once amendments (if
any) are made, the haematologist signs the TS. The
second page of the SCP is patient centred and popu-
lated by the nurse in consultation with the participant.
Participants will be asked to identify three main con-
cerns, health goals and proposed actions to achieve
these goals.
Sample size
The calculation of a sample size is not required for pilot
RCTs as effect size is not yet known. Rather the purpose
of the pilot is to determine variability in measures from
which effect sizes can be calculated. Approximately 75
patients are seen per year at the study setting; however,
this figure is inclusive of new and existing patients.
Therefore, a consecutive sample of 60 participants will
be recruited and randomised 1:1 to either control or
intervention group (30 participants are expected in
each group). It is necessary to establish test–retest reli-
ability for the SF-SUNS by demonstrating a minimum
intraclass correlation (ICC) of 0.8. Therefore, a sample
size of 39 (rounded up to 40 participants) administered
on two consecutive occasions no more than 5 days apart
(baseline and 5 days later) is required to achieve 80%
power to detect this ICC of 0.8.48
Patient-reported outcome measures
A review of the literature44 has resulted in four assess-
ment instruments being selected to measure the out-
comes proposed: SF-SUNS; Depression Anxiety Stress
Scale (DASS21); Mini-Mental Adjustment to Cancer
Scale (Mini-MAC); and Patient Empowerment Scale
(PES). These instruments have demonstrated reliability
and validity with haematological cancer survivors as
shown in table 1.
Baseline data collection
Baseline data collection from consenting participants
will occur 3 months after treatment completion. All par-
ticipants will self-report demographic information and
complete the four assessment instruments. In addition,
they will receive a second SF-SUNS instrument to com-
plete no later than 5 days after the baseline testing.
These will be returned via a reply-paid envelope to allow
the researchers to undertake test–retest reliability
testing. Medical demographic information obtained will
include type of haematological cancer, stage of disease,
type of treatment received (chemotherapy, immunother-
apy, radiotherapy), date of diagnosis, time since diagno-
sis, treatment complications or dose modifications, and
comorbidities. Personal demographic information col-
lected will include sex, age, marital status, age of chil-
dren (if any), postcode, occupation, income level,
education level and health behaviours such as smoking,
alcohol consumption and weight.
Randomisation
After baseline assessment, participants will be rando-
mised to either the current standard of care or interven-
tion group. Computer-generated random numbers using
a four-digit sequence have been generated and linked to
group allocation by an independent statistician. An inde-
pendent member of the research team, to ensure confi-
dentiality and offset bias in randomisation, has sealed a
hard copy of each individual number and group in an
opaque envelope. The envelopes are consecutively num-
bered and will be distributed to consenting participants
in this order. Control group participants will be made
aware that another researcher will follow-up non-
questionnaire return with a telephone call to the partici-
pant after 2 weeks.
Control group
Control group participants will receive follow-up care as
per haematologists’ usual practice. At 3 and 6 months
after baseline, the same four assessment instruments will
be sent to the participant, and they will self-report any
issues or unmet supportive care needs. An addressed
reply paid envelope will be provided to return assess-
ments. Participants who score high unmet needs will be
encouraged to discuss these with their haematologist at
their usual follow-up appointment.
Intervention group
Following baseline data collection, intervention group
participants will have an appointment at the nurse-led
lymphoma survivorship clinic. The first page of the SCP
TS will be populated prior to this appointment. At the
first nurse-led lymphoma survivorship clinic, any con-
cerns the participant has regarding the end of treatment
will be discussed and normalised. The nurse will discuss
the TS and potential late effects. The second page of the
SCP will be completed by the nurse using an electronic
template in collaboration with the participant. At this
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Table 1 Outcomes assessment instruments
Instrument Use Items and factors Internal consistency Additional issues
Short-Form Survivor
Unmet Needs Survey
(SF-SUNS)49
Developed for cancer survivors to
assess unmet needs. Assess the gap
between patient self-reported
concerns and the level of support they
require
Discriminates between survivors at
different stages post-treatment
completion
30 items—0 (no unmet need) to 4 (very
high unmet need
Four factors: information (3 items);
financial concerns (8 items); access and
continuity of care (6 items); relationships
and emotional health (13 items)
Cronbach’s α scores for all
domains were ≥0.85
intraclass correlation (ICC)
across all domains high, ie,
≥0.9 indicating SF-SUNS
reliably measured the level of
unmet need
Test–retest reliability not
established
Will be undertaken
during this study
Depression Anxiety
Stress Scale
(DASS-21)50
Measures multiple dimensions of
depression, anxiety and stress
Three 7-item scales—0 (did not apply to
me at all) to 3 (applied to me very much,
or most of the time)
5 subscale severity ratings: normal, mild,
moderate, severe and extremely severe
Cronbach’s α subscale scores
were: 0.94 depression; 0.87
anxiety; and 0.91 stress51
Used to support SUNS
psychometric properties
in haematology cancer
survivors
Mini-Mental
Adjustment to Cancer
Scale (Mini-MAC)52
Measures cancer-specific coping
strategies
29 items—5 cancer-specific coping
strategies: helplessness–hopelessness
(8 items); anxious preoccupation (8 items);
fighting spirit (4 items); cognitive
avoidance (4 items); and fatalism
(5 items).
Scale-1 (definitely does not apply to me)
to 4 (definitely applies to me)
Reliability using Cronbach’s α
coefficients for each subscale
ranged from 0.62 to 0.88
Used with small sample
of haematology cancer
survivors
Patient Empowerment
Scale (PES)53
Measures level of patient’s coping
ability and self-efficacy in terms of
managing their illness and making
decisions about support strategies
15-item 4-point Likert-type scale A high degree of reliability has
been established using the
Rasch Extended Model with the
Person Separation Index of
0.926
Used in haematology/
oncology patients
Cronbach’s α is considered a measure of scale reliability and a high score indicates good internal consistency reliability of the test.
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time, the importance of follow-up recommendations will
be emphasised. The SCP will then be printed, signed
and dated by the participant and the nurse. The com-
pleted SCP TS will then be copied, with the original
given to the participant, a copy placed in the partici-
pant’s medical records and a copy sent to their GP.
Motivational interviewing techniques will be employed
for healthy lifestyle behaviours and to assess for readiness
to make behavioural change. Participants will be encour-
aged to identify and explore behaviours they would like
to modify using a chart that enables them to list likes
and dislikes of specific behaviours and potential impacts
of perceived behavioural change. By listening to con-
cerns, highlighting conflicts arising from behaviour and
documenting on the chart will potentially enable partici-
pants to assume control of decision-making related to
behavioural change. Participants will be encouraged to
set realistic time frames and identify habits and beliefs
that may possibly be hindering change. Tailored
evidenced-based information and advice in a resource
pack will then be issued. It is anticipated that a consult-
ation of 60 min will be required in a private clinic room.
A further two appointments will be made at 3 and
6 months after baseline, where the same four assessment
instruments will be completed by the participant, and
they will self-report any issues or unmet supportive care
needs. These will be discussed and the appropriate
resources, support and information provided.
Participants will be encouraged to discuss their health
concerns, goals and progress with any action they may
have taken. Participants will be asked if they have seen
their GP in the last 3 months and if they took the SCP TS
and discussed any of the late-effect screening recommen-
dations, their participant-identified concerns or goals.
This will aid the transition to GP follow-up where the
benefits of shared care will be explained. A checklist for
each participant of the resources provided will be kept.
DATA ANALYSIS
Quantitative data will be analysed using univariate and
multivariate statistical techniques with SPSS data analysis
software. Descriptive statistics will be used to analyse the
demographic variables collected. Responses to the
SF-SUNS, DASS21, Mini-MAC and PES will be scored
according to the algorithms in the instrument manuals.
Measures from all instruments will be checked for
normal variance within the two groups. Within each
group, paired t test comparisons will be made between
baseline measurements and at each time point: baseline,
3 months and 6 months. Differences between interven-
tion and control groups will then be assessed at each
time point. Test–retest reliability using ICC will be
undertaken on the SF-SUNS instrument. The minimum
ICC value required for this scale is 0.8. Participants who
drop out or are lost to follow-up or need to be excluded
after the start will be accounted for by intention-to-treat
analyses. CIs will reflect the contrast between groups to
show treatment effect. Missing data, incomplete answers
and non-response will be recorded.
Qualitative interviews
Supplementary in-depth, semistructured interviews will
occur with ∼10 consenting participants when they have
completed all intervention components (after
6 months). This number will allow for saturation of
themes.54–56 Telephone interviews will be digitally
recorded and undertaken by an independent researcher
to ensure participants are given the opportunity to freely
express positive and negative perceptions of their experi-
ence. The use of a qualitative approach will provide
depth of information regarding the personal impact of
the nurse-led lymphoma survivorship clinic on the par-
ticipant. The interviews will also highlight any issues or
challenges for this group that could be better addressed
in the future.
Interviews will be transcribed verbatim and thematic
analysis used to determine themes and patterns within
the text.57–59 QSR NVivo qualitative analysis data man-
agement software will be used to manage interview data.
GP evaluations
A non-validated evaluation will be sent to GPs who have
received the SCP TS. This was developed in consultation
with a GP and will ascertain if GPs made use of the SCP
TS and to elicit perceptions of the value and effective-
ness of this document in facilitating communication
between the treating hospital and GP, and GP and par-
ticipant. This will guide future refinement of the SCP
TS. Analysis will use descriptive statistics and distribution
analysis techniques. Open-ended questions will use
content analysis techniques. GPs will be called by the
researcher after 2 weeks for non-return of the question-
naire to remind them to fill in and return the evaluation
in the reply-paid envelope.
DISCUSSION
A significant culture change is required for providers to
recognise survivorship care as a standard component of
quality cancer care that involves all health professionals,
participants and families. The gap in knowledge contri-
butes to a current model of survivorship care that is frag-
mented, with inadequate service provision at treatment
completion, leading to unmet needs along the survivor-
ship continuum.60 The cancer specialist is not necessar-
ily required for routine screening and follow-up.
However, the involvement of other health professionals,
including primary care, necessitates the need for an
awareness of the treatment delivered and the long-term
and late-effect risks.8
This study will address the lack of robust empirical evi-
dence in haematology survivorship care. A nurse-led
model of care would assist patients transitioning from
the end of treatment to the survivorship phase.
Furthermore, the provision of an individualised SCP TS
Taylor K, et al. BMJ Open 2016;6:e010817. doi:10.1136/bmjopen-2015-010817 7
Open Access
is a means to empower individuals with knowledge
about their disease and treatment and to assume respon-
sibility for future surveillance and disease management.
It will likewise take advantage of ‘teachable moments’ at
the end of active treatment to support and promote
patient participation in healthy lifestyle behaviours.38
This is particularly vital for younger survivors, given the
expectation of a longer survivorship period.40
The intervention has been timed to occur in the early
survivorship phase. This has been supported by prelim-
inary focus group work including lymphoma cancer sur-
vivors who indicated they often felt abandoned at
treatment completion.22 This timing also concords with
McDowell et al,29 who found assessments and interven-
tions undertaken in the early survivorship phase (up to
2 years post diagnosis) led to fewer unmet needs moving
into the extended survivorship phase (over 5 years).
The CALy trial will examine the impact and effective-
ness of the nurse-led lymphoma survivorship clinic inter-
vention through an assessment of the important clinical
outcomes: unmet informational and practical needs;
depression, anxiety and stress; coping; and self-
empowerment as measured by the instruments chosen.
It is therefore designed to improve the identification of
unmet needs. Testing of such an intervention by an RCT
has not been published in lymphoma survivorship
studies to date. Consequently, it will make a significant
contribution to the planning and delivery of survivorship
care. Likewise, it represents a substantial and original
contribution to knowledge and support for haematology
survivorship care as few studies aim to improve the psy-
chosocial and supportive care of this cohort. If the inter-
vention achieves its intended outcomes, it may
potentially lead to the development of nurse-led haema-
tology survivorship clinics across the tertiary health
sector in Western Australia that could ultimately be
expanded to all cancer survivors.
Ethics
Ethics approval has been gained from the relevant hos-
pital (2015-020) and university (015007F) Human
Research Ethics Committees (HRECs). The trial is regis-
tered at the Australian and New Zealand Clinical Trials
Registry (ACTRN 1261500530527) and the Western
Australia Cancer Clinical Trials Registry. The trial is
open to patient recruitment. It is not expected partici-
pants will be exposed to any undue risks or harm by par-
ticipation. Participant information will remain
confidential and deidentified where appropriate.
Economic harm will be minimised by providing appoint-
ments when the participant is already attending the hos-
pital. Exploring concerns may be distressing and if this
occurs, participants will be referred to the appropriate
counselling services as per usual clinical practice.
Collected data will be securely stored at the university
for 15 years after study completion and will only be
accessible with written permission from the researcher
and relevant university and hospital sites.
Dissemination
We plan to complete the study by December 2017 and
report trial results in 2018. It is anticipated the main trial
outcomes will be published in a single paper in a refer-
eed cancer journal. Further publications will explore the
qualitative data and the test–retest reliability measures of
the SF-SUNS. We will correspondingly present findings at
national and international conferences.
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